TY-0540 demonstrates activity in different tumor models, including palbociclib-resistant models
May 11, 2023
Researchers from TYK Medicines Inc. presented the discovery and preclinical evaluation of a new cyclin-dependent kinase 274/6 (CDK2/4/6) inhibitor, TY-0540, being developed as an anticancer agent.
